文献类型：期刊文献

英文题名：The Efficacy of Aprepitant in Preventing Post-bariatric Surgery Nausea and Vomiting: Evidence from Clinical Trials

作者：Zhu, Chenglou[1,2,3];Zhao, Tiantian[2];Wu, Qiong[1];Da, Mingxu[1,2,3]

第一作者：Zhu, Chenglou

通信作者：Zhu, CL[1];Da, M[1];Zhu, CL[2];Da, M[2];Zhu, CL[3];Da, M[3]

机构：[1]Lanzhou Univ, Sch Clin Med 1, Lanzhou 730000, Peoples R China;[2]Gansu Univ Chinese Med, Sch Clin Med 1, Lanzhou 730000, Peoples R China;[3]Gansu Prov Hosp, Dept Surg Oncol, Lanzhou 730000, Peoples R China

第一机构：Lanzhou Univ, Sch Clin Med 1, Lanzhou 730000, Peoples R China

通信机构：[1]corresponding author), Lanzhou Univ, Sch Clin Med 1, Lanzhou 730000, Peoples R China;[2]corresponding author), Gansu Univ Chinese Med, Sch Clin Med 1, Lanzhou 730000, Peoples R China;[3]corresponding author), Gansu Prov Hosp, Dept Surg Oncol, Lanzhou 730000, Peoples R China.|[10735]甘肃中医药大学;

年份：2024

卷号：34

期号：7

起止页码：2617

外文期刊名：OBESITY SURGERY

收录：;Scopus(收录号：2-s2.0-85195586521);WOS:【SCI-EXPANDED(收录号:WOS:001243659300002)】；

基金：This work was supported by the Natural Science Foundation of Gansu Province (grant number 23JRRA1317).

语种：英文

外文关键词：Aprepitant; Metabolic bariatric surgery; Nausea and vomiting; Meta-analysis

摘要：Introduction This study aims to evaluate the effectiveness of aprepitant in preventing postoperative nausea and vomiting (PONV) following metabolic bariatric surgery (MBS). Methods Clinical trials meeting the inclusion criteria were identified through searches of PubMed, Embase, and the Cochrane Library databases, as well as clinical trials registered at clinicaltrials. gov. These trials compared aprepitant with the control or placebo groups among patients who underwent MBS. Meta-analysis was performed using StataSE 17.0 software to calculate the pooled risk ratio (RR) and its 95% confidence interval (CI) to assess the effectiveness of aprepitant in preventing PONV following MBS. Results A total of five articles comprising six studies including 929 patients undergoing MBS were included. Meta-analysis revealed a significant reduction in the incidence of PONV among patients receiving aprepitant (pooled RR = 0.51, 95% CI: 0.38-0.68, P < 0.05). Subgroup analysis indicated that aprepitant effectively reduced PONV incidence at 0, 6, and 12 h postoperatively in patients with MBS, but did not decrease PONV occurrence at 24 and 48 h postoperatively. Conclusion Aprepitant demonstrated significant clinical efficacy in preventing PONV following MBS, effectively reducing patient discomfort, and improving postoperative recovery. Therefore, aprepitant should be considered a preventive measure in patients undergoing MBS to enhance patient satisfaction and recovery rates. Additionally, to maintain an effective drug concentration, aprepitant should be administered within the first 24 h postoperatively. PROSPERO Registration CRD 42024528154.